vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and FRANKLIN STREET PROPERTIES CORP (FSP). Click either name above to swap in a different company.
FRANKLIN STREET PROPERTIES CORP is the larger business by last-quarter revenue ($26.0M vs $15.0M, roughly 1.7× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -28.1%, a 29.9% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -8.2%). CHAMPIONS ONCOLOGY, INC. produced more free cash flow last quarter ($-2.0M vs $-12.7M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -8.7%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Franklin Street Properties Corp is a Massachusetts-based real estate investment trust (REIT) in the United States. It primarily invests in, owns, and operates high-quality office properties across major U.S. metropolitan markets, serving corporate tenants across various industry segments, and delivers stable long-term returns via rental income and strategic asset management.
CSBR vs FSP — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $26.0M |
| Net Profit | $268.0K | $-7.3M |
| Gross Margin | 51.7% | 59.4% |
| Operating Margin | 1.2% | -27.9% |
| Net Margin | 1.8% | -28.1% |
| Revenue YoY | 11.5% | -8.2% |
| Net Profit YoY | -63.2% | 14.1% |
| EPS (diluted) | $0.02 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $26.0M | ||
| Q3 25 | $14.0M | $27.3M | ||
| Q2 25 | $12.4M | $26.7M | ||
| Q1 25 | $17.0M | $27.1M | ||
| Q4 24 | $13.5M | $28.4M | ||
| Q3 24 | $14.1M | $29.7M | ||
| Q2 24 | $14.0M | $30.8M | ||
| Q1 24 | $12.0M | $31.2M |
| Q4 25 | $268.0K | $-7.3M | ||
| Q3 25 | $-436.0K | $-8.3M | ||
| Q2 25 | $-1.8M | $-7.9M | ||
| Q1 25 | $4.5M | $-21.4M | ||
| Q4 24 | $728.0K | $-8.5M | ||
| Q3 24 | $1.3M | $-15.6M | ||
| Q2 24 | $-109.0K | $-21.0M | ||
| Q1 24 | $-2.5M | $-7.6M |
| Q4 25 | 51.7% | 59.4% | ||
| Q3 25 | 42.9% | 60.9% | ||
| Q2 25 | 41.1% | 59.9% | ||
| Q1 25 | 61.2% | 62.8% | ||
| Q4 24 | 44.9% | 59.7% | ||
| Q3 24 | 49.7% | 61.0% | ||
| Q2 24 | 48.2% | 64.2% | ||
| Q1 24 | 34.7% | 64.7% |
| Q4 25 | 1.2% | -27.9% | ||
| Q3 25 | -3.8% | -30.5% | ||
| Q2 25 | -16.2% | -29.2% | ||
| Q1 25 | 26.4% | -78.9% | ||
| Q4 24 | 5.4% | -29.9% | ||
| Q3 24 | 9.5% | -52.4% | ||
| Q2 24 | -1.9% | -68.0% | ||
| Q1 24 | -21.4% | -24.0% |
| Q4 25 | 1.8% | -28.1% | ||
| Q3 25 | -3.1% | -30.5% | ||
| Q2 25 | -14.9% | -29.5% | ||
| Q1 25 | 26.4% | -79.1% | ||
| Q4 24 | 5.4% | -30.0% | ||
| Q3 24 | 9.3% | -52.6% | ||
| Q2 24 | -0.8% | -68.2% | ||
| Q1 24 | -21.1% | -24.2% |
| Q4 25 | $0.02 | $-0.06 | ||
| Q3 25 | $-0.03 | $-0.08 | ||
| Q2 25 | $-0.12 | $-0.08 | ||
| Q1 25 | $0.31 | $-0.21 | ||
| Q4 24 | $0.05 | $-0.09 | ||
| Q3 24 | $0.09 | $-0.15 | ||
| Q2 24 | $-0.01 | $-0.20 | ||
| Q1 24 | $-0.19 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $30.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $607.0M |
| Total Assets | $30.2M | $892.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $30.6M | ||
| Q3 25 | $10.3M | $31.4M | ||
| Q2 25 | $9.8M | $29.4M | ||
| Q1 25 | $3.2M | $30.2M | ||
| Q4 24 | $2.8M | $41.1M | ||
| Q3 24 | $2.9M | $40.9M | ||
| Q2 24 | $2.6M | $30.2M | ||
| Q1 24 | $4.5M | $34.2M |
| Q4 25 | $4.2M | $607.0M | ||
| Q3 25 | $3.5M | $615.3M | ||
| Q2 25 | $3.8M | $624.7M | ||
| Q1 25 | $5.5M | $633.4M | ||
| Q4 24 | $681.0K | $655.9M | ||
| Q3 24 | $-332.0K | $665.4M | ||
| Q2 24 | $-1.9M | $682.1M | ||
| Q1 24 | $-2.1M | $703.9M |
| Q4 25 | $30.2M | $892.9M | ||
| Q3 25 | $30.5M | $901.0M | ||
| Q2 25 | $32.3M | $903.2M | ||
| Q1 25 | $30.6M | $916.4M | ||
| Q4 24 | $25.2M | $946.9M | ||
| Q3 24 | $24.9M | $981.5M | ||
| Q2 24 | $26.1M | $1.0B | ||
| Q1 24 | $26.8M | $1.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $3.8M |
| Free Cash FlowOCF − Capex | $-2.0M | $-12.7M |
| FCF MarginFCF / Revenue | -13.1% | -48.6% |
| Capex IntensityCapex / Revenue | 1.6% | 63.0% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-25.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $3.8M | ||
| Q3 25 | $600.0K | $8.3M | ||
| Q2 25 | $6.9M | $-2.9M | ||
| Q1 25 | $490.0K | $-5.5M | ||
| Q4 24 | $-283.0K | $9.0M | ||
| Q3 24 | $311.0K | $14.5M | ||
| Q2 24 | $-1.8M | $-648.0K | ||
| Q1 24 | $-919.0K | $-7.1M |
| Q4 25 | $-2.0M | $-12.7M | ||
| Q3 25 | $554.0K | $3.0M | ||
| Q2 25 | $6.6M | $-5.7M | ||
| Q1 25 | $448.0K | $-9.9M | ||
| Q4 24 | $-377.0K | $-16.2M | ||
| Q3 24 | — | $8.6M | ||
| Q2 24 | $-1.8M | $-5.1M | ||
| Q1 24 | $-1.0M | $-15.8M |
| Q4 25 | -13.1% | -48.6% | ||
| Q3 25 | 4.0% | 11.0% | ||
| Q2 25 | 53.5% | -21.5% | ||
| Q1 25 | 2.6% | -36.7% | ||
| Q4 24 | -2.8% | -57.2% | ||
| Q3 24 | — | 29.1% | ||
| Q2 24 | -13.0% | -16.7% | ||
| Q1 24 | -8.4% | -50.8% |
| Q4 25 | 1.6% | 63.0% | ||
| Q3 25 | 0.3% | 19.4% | ||
| Q2 25 | 2.0% | 10.7% | ||
| Q1 25 | 0.2% | 16.4% | ||
| Q4 24 | 0.7% | 88.9% | ||
| Q3 24 | 0.0% | 19.6% | ||
| Q2 24 | 0.0% | 14.6% | ||
| Q1 24 | 0.8% | 28.1% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
FSP
Segment breakdown not available.
